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ues to change as new chemotherapy agents are developed.
These results suggest that therapies that avoid or amelio-
rate the most troublesome side-effects would be preferred
agents.
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OBJECTIVES: Various disease speciﬁc instruments exist
to measure treatment satisfaction and patient preference.
Subsequently, data from these instruments have been used
to differentiate treatment options. Several measurements
exist to assess satisfaction with oncology care, but few
tools exist to measure satisfaction with or preferences for
oncology treatments. As the paradigm in oncology shifts
from treating and managing cancer as a terminal disease
to a chronic disease and with an increasing number of
treatment options, the need to assess patients’ perceptions
and preferences regarding treatment becomes more
evident. The purpose of this study was to review and
compare characteristics of instruments within oncology
studies that assessed aspects of treatment satisfaction and
patient preference.
METHODS: Publications involving oncology patients,
treatment satisfaction, and patient preference were 
identiﬁed through the search of available literature 
within MEDLINE and CANCERLIT.
RESULTS: The search did not identify a comprehensive
patient treatment satisfaction instrument. Selected 
ﬁndings included the preference for: oral rather than
intravenous medication; treatment at home over outpa-
tient clinic care; and follow-up care with primary physi-
cians rather than oncologists. Findings with respect to
patient preference for using chemotherapy revealed that
survival and toxicity trade-off differed between patients
with different tumor types. Breast cancer patients are
more willing to accept aggressive treatment with severe
side effects in exchange for minimal to no increase in sur-
vival rates. Non-small cell lung cancer patients, on the
other hand, are not as willing to undergo chemotherapy
and prefer a signiﬁcant increase in survival duration with
minimal toxicity.
CONCLUSIONS: Various techniques have been used to
assess aspects of patient satisfaction and preference with
treatment. However, the application of these instruments
in oncology is not yet widespread. The availability of a
tool that combines these measurements into one instru-
ment would be valuable when evaluating new therapies
compared to standard of care regimens.
PCN19
USE OF THE EUROQOL VISUAL ANALOGUE
SCALE IN ASSESSING LONGITUDINAL
CHANGES IN QUALITY OF LIFE IN CANCER
PATIENTS:A COMPARISON WITH SUBSCALES
OF THE MEDICAL OUTCOMES SURVEY SHORT
FORM-36
Castel LD1, Reed SD1,Weinfurt KP1, Li Y1, Law AW1,
Meropol NJ2, Schulman KA1
1Duke Clinical Research Institute, Durham, NC, USA;
2Fox Chase Cancer Center, Philadelphia, PA, USA
OBJECTIVE: To examine the relative contributions 
of mental and physical health to evaluations of health
preference for advanced-stage cancer patients in a 
longitudinal setting.
METHODS: We compared changes in the Physical 
Component Summary (PCS) and Mental Component
Summary (MCS) scores of the Medical Outcomes Survey
Short Form (SF-36) with changes in the EuroQoL visual
analogue scale (VAS) for a sample of advanced-stage
cancer patients. Using data collected at baseline and 3-
month followup in a multicenter study of 328 cancer
patients eligible for phase I clinical trials, we examined
correlations among change-from-baseline scores for the
PCS, MCS, and VAS.
RESULTS: Mean age was 57.5 years; 10 different types
of malignancies were represented in the sample. Com-
pleters (144 patients who completed both baseline and
follow-up questionnaires) had a signiﬁcantly (p = 0.01)
higher average baseline PCS score (M = 41.5, SD+/- 10.1)
than non-completers (M = 38.3, SD+/- 12.3), whereas
baseline MCS and VAS scores did not differ between the
two groups (p = 0.74 and 0.28, respectively). Change-
from-baseline in the VAS (M = -5.7, SD+/-21.8) was 
positively correlated (r = 0.34, p = 0.0002) with changes
in the PCS (M = -4.1, SD+/-9.9), and was positively 
correlated (r = 0.23, p = 0.0123) with changes in the 
MCS (M = -1.1, SD+/-9.7). While the distribution of 
VAS change scores was more piqued, there was greater
variability in MCS and PCS change scores.
CONCLUSIONS: Changes in overall mental and physi-
cal health contribute approximately equally to changes 
in advanced-stage cancer patients’ preferences for their
current health states. Our ability to detect strong corre-
lations between changes in the VAS preference measure
and changes in the MCS and PCS health status measures
was limited by lack of variability in change scores for 
the preference measure used. Further research should
examine longitudinal relationships between other prefer-
ence measures (i.e. standard gamble and time-tradeoff)
and generic health status measures.
